Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple supplements may fight muscle loss in COPD

NCT ID NCT07288619

Disease control Sponsor: Safeer Khan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether omega-3 fatty acids and vitamin D supplements can improve weight, muscle mass, and fatigue in 45 people with COPD who also have cachexia (severe muscle wasting). Participants took the supplements twice daily for six weeks. The goal was to see if these nutrients could help manage the metabolic problems that make cachexia worse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Omega-3 fatty acids and vitamin D supplements
What this could lead to
If effective, these supplements could offer a simple, low-cost way to help COPD patients with cachexia maintain weight and muscle strength.
What could go wrong
This is a small, completed trial with only 45 participants, so results may not apply widely. Supplements may cause mild side effects and are not a cure for COPD or cachexia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Oct 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able to provide both written and verbal consent. 2. Clinically diagnosed with chronic obstructive pulmonary disease (COPD). 3. Diagnosis of pulmonary cachexia according to Cachexia Consensus Conference criteria Exclusion Criteria: 1. Patients experiencing acute exacerbations of COPD. 2. Patients with co-morbid chronic diseases that can also cause cachexia, including cancer, HIV/AIDS, heart failure, chronic renal failure, liver cirrhosis, and rheumatoid arthritis 3. Pregnant women and patients with abnormal liver and/or renal function tests. 4. Patients who have taken n-3 PUFAs, Vitamin D, or any intervention for cachexia in the past four weeks. 5. Patients on oral or parenteral corticosteroids for more than four weeks. 6. Patients with a history of allergies to fish-derived products, n-3 polyunsaturated fatty acids (PUFAs), or Vitamin D. 7. Patients with a metabolic disorder that can lead to changes in body composition.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cachexia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cachexia chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cachexia Chronic obstructive pulmonary disease (COPD)

Contacts and locations

Locations

  • Gulab Devi Teaching Hospital, Lahore

    Lahore, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.